| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H38N2O7S |
| Molecular Weight | 546.676 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCC[C@]1(CC)CS(=O)(=O)C2=C(C=C(OC)C(CNC(CC(O)=O)CC(O)=O)=C2)[C@H](N1)C3=CC=CC=C3
InChI
InChIKey=CZGVOBIGEBDYTP-VSGBNLITSA-N
InChI=1S/C28H38N2O7S/c1-4-6-12-28(5-2)18-38(35,36)24-13-20(17-29-21(14-25(31)32)15-26(33)34)23(37-3)16-22(24)27(30-28)19-10-8-7-9-11-19/h7-11,13,16,21,27,29-30H,4-6,12,14-15,17-18H2,1-3H3,(H,31,32)(H,33,34)/t27-,28-/m1/s1
| Molecular Formula | C28H38N2O7S |
| Molecular Weight | 546.676 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
GSK-2330672 (linerixibat) is a nonabsorbable apical sodium-dependent bile acid transporter. This compound is being evaluated for treatment in patients with type 2 diabetes. In animal models of type 2 diabetes, it lowers glucose levels. GSK-2330672 also improves glucose and lipids in diabetes patients, but a high incidence of gastrointestinal adverse events (such as diarrhea) has been reported. Efficacy of GSK-2330672 in patients with primary biliary cholangitis that develop itch (pruritus) has also been examined. However, long-term used might be problematic because of the gastrointestinal adverse events.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 42.0 nM [IC50] |
Patents
|
|
TARGET -> INHIBITOR |
IC50
|
Showing 1 to 1 of 1 entries
